Biogen, Inc. (NASDAQ/BGEN) today announced it has licensed from Genentech, Inc. (NYSE/DNA) worldwide, patent rights relating to fusion proteins, described as immunoadhesons. The non-exclusive licenses will apply to AMEVIVE® (alefacept), currently approved in the United States for moderate-to-severe chronic plaque psoriasis, and other potential products in Biogen’s product pipeline.
Biogen will pay an undisclosed royalty to Genentech beginning immediately. This has already been incorporated in Biogen’s financial guidance for 2003.
Biogen is the world’s oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients’ lives around the world through its global marketing capabilities. For press releases and additional information about the company, please visit http://www.biogen.com.
Associate Director, Public Affairs
Tel: (617) 914-6524
Investment Community Contact:
Manger, Investor Relations
Tel: (617) 679-2812